An interventional study of NMN and Placebo in Immunosenescence, Overweight and Obesity, sponsored by Qing Su. Completed at 1 site in China. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Qing Su · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.
Among the 603 studies in Obesity with a site in China, this one is the 235th largest by enrollment of the 504 interventional ones that give a count, is one of 115 that started in 2025, is one of 213 with no phase, and was the 334th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:
Chendu DIAO Pharmaceutical Group CO., LTD. · Sites in China
Ages 18–65
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Argentina and 8 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 50 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
603 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 103 · Phase 2 70 · Phase 3 108 · Phase 4 28
First in 1997; this study’s year is marked. 115 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 120 across the 504 interventional studies, 320 across the 99 observational. Of the 242 that completed or were terminated, 13 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
241 of 603 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Qing Su as lead sponsor.
Qing Su has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
106 of the studies in Obesity with a site in China that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
Add all 106 to your calendar (.ics) → With an account.
Among the 603 studies in Obesity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates whether nicotinamide mononucleotide (NMN) sustained-release tablets affect markers of immune system aging in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. It compares NMN, 1,000 mg once daily for 26 weeks, with a matching placebo. The main assessment is the change from baseline in the proportion of a blood T-cell population associated with immune system aging. The study also evaluates liver fat, blood sugar regulation, body composition, other immune and metabolic markers, and cardiorespiratory fitness, together with laboratory measures of safety.
This single-center, randomized, placebo-controlled, parallel-group study evaluates the effects of nicotinamide mononucleotide (NMN) sustained-release tablets on immunosenescence and metabolism in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. A total of 124 participants were enrolled. Participants were randomly assigned to receive NMN sustained-release tablets (1,000 mg per tablet) or matching placebo, one tablet daily before breakfast for 26 weeks. Study visits were scheduled at months 1, 3, and 6.
The primary outcome is the change from baseline to Week 26 in the percentage of CD3+CD8+CD27-CD28- T cells among total CD3+CD8+ T cells in peripheral blood, measured by flow cytometry. The change is calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Secondary assessments include other T-cell phenotypes, the CD8/CD4 ratio expressed as a percentage, hepatic steatosis, glucose metabolism, pancreatic beta-cell function, insulin resistance, body composition, anthropometric measures, whole-blood NMN and NAD+ concentrations, relative telomere length, and cardiorespiratory fitness. Hepatic steatosis is assessed using magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and the controlled attenuation parameter (CAP) measured by FibroScan. Body composition outcomes, assessed by dual-energy X-ray absorptiometry (DXA), are total body fat mass, total body tissue fat percentage, total body lean mass, estimated visceral adipose tissue mass, and relative skeletal muscle index. Cardiorespiratory fitness outcomes, assessed by cardiopulmonary exercise testing, are peak oxygen uptake and oxygen uptake at the anaerobic threshold. Each secondary outcome is assessed as the change from baseline to Week 26 and analyzed separately.
Safety assessments include routine blood and urine tests and liver and kidney function tests.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's enrollment of 124 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →This is the only study on the registry with Qing Su as lead sponsor.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Nov 3, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the NMN arm receive one sustained-release tablet containing 1,000 mg of nicotinamide mononucleotide orally once daily before breakfast for 26 weeks.
Dietary Supplement: NMN
Participants assigned to the placebo arm receive one matching placebo tablet orally once daily before breakfast for 26 weeks.
Dietary Supplement: Placebo
Nicotinamide mononucleotide (NMN) sustained-release tablets, 1,000 mg per tablet, administered orally as one tablet once daily before breakfast for 26 weeks.
Matching placebo tablets, administered orally as one tablet once daily before breakfast for 26 weeks.
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD27-CD28- T Cells Among Total CD3+CD8+ T Cells
The percentage of CD3+CD8+CD27-CD28- T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD27- T Cells Among Total CD3+CD8+ T Cells
The percentage of CD3+CD8+CD27- T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD28- T Cells Among Total CD3+CD8+ T Cells
The percentage of CD3+CD8+CD28- T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD27- T Cells Among Total CD3+CD4+ T Cells
The percentage of CD3+CD4+CD27- T cells among total CD3+CD4+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD28- T Cells Among Total CD3+CD4+ T Cells
The percentage of CD3+CD4+CD28- T cells among total CD3+CD4+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD27-CD28- T Cells Among Total CD3+CD4+ T Cells
The percentage of CD3+CD4+CD27-CD28- T cells among total CD3+CD4+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD45RA+CCR7- T Cells Among Total CD3+CD8+ T Cells
The percentage of CD3+CD8+CD45RA+CCR7- T cells (TEMRA cells) among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD57+KLRG1+ T Cells Among Total CD3+CD8+ T Cells
The percentage of CD3+CD8+CD57+KLRG1+ T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the CD3+CD8+ to CD3+CD4+ T-Cell Ratio Expressed as a Percentage
CD3+CD8+ and CD3+CD4+ T cells in peripheral blood will be quantified by flow cytometry. The CD8/CD4 ratio will be expressed as a percentage by dividing the number of CD3+CD8+ T cells by the number of CD3+CD4+ T cells and multiplying by 100. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Liver Fat Content Assessed by MRI-PDFF
Liver fat content will be assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and expressed as a percentage. Change from baseline will be calculated as the Week 26 MRI-PDFF percentage minus the baseline MRI-PDFF percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Controlled Attenuation Parameter (CAP)
Hepatic steatosis will be assessed using the controlled attenuation parameter (CAP) measured by FibroScan and expressed in dB/m. Change from baseline will be calculated as the Week 26 CAP value minus the baseline CAP value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Fasting Blood Glucose
Fasting blood glucose will be measured in venous blood and expressed in mmol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in 2-Hour Blood Glucose During an Oral Glucose Tolerance Test
Blood glucose at 2 hours during an oral glucose tolerance test (OGTT) will be measured in venous blood and expressed in mmol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Glycated Hemoglobin (HbA1c)
Glycated hemoglobin (HbA1c) will be measured in whole blood and expressed as a percentage (%) of total hemoglobin. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in HOMA-beta
Pancreatic beta-cell function will be assessed using the homeostasis model assessment of beta-cell function (HOMA-beta), calculated from fasting glucose and fasting insulin and reported as an index. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in HOMA-IR
Insulin resistance will be assessed using the homeostasis model assessment of insulin resistance (HOMA-IR), calculated from fasting glucose and fasting insulin and reported as a unitless index. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Total Body Fat Mass Assessed by DXA
Total body fat mass will be measured by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in g. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Total Body Tissue Fat Percentage Assessed by DXA
Total body tissue fat percentage (fat mass as a percentage of total tissue mass) will be measured by whole-body dual-energy X-ray absorptiometry (DXA). Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Total Body Lean Mass Assessed by DXA
Total body lean mass will be measured by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in g. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Estimated Visceral Adipose Tissue Mass Assessed by DXA
Visceral adipose tissue mass will be estimated by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in g. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Relative Skeletal Muscle Index (RSMI) Assessed by DXA
Relative skeletal muscle index (RSMI), calculated as appendicular lean mass divided by height squared, will be measured by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in kg/m\^2. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Body Weight
Body weight will be measured using a weighing scale and expressed in kilograms. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Waist Circumference
Waist circumference will be measured using a tape measure and expressed in centimeters. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Waist-to-Hip Ratio
Waist and hip circumferences will be measured using a standardized tape measure following WHO measurement protocols. The waist-to-hip ratio will be calculated by dividing waist circumference by hip circumference, using the same units for both measurements. The ratio is unitless. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Waist-to-Height Ratio
Waist circumference and height will be measured following WHO measurement protocols. The waist-to-height ratio will be calculated by dividing waist circumference by height, using the same units for both measurements. The ratio is unitless. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Whole-Blood Nicotinamide Mononucleotide (NMN) Concentration
Nicotinamide mononucleotide (NMN) concentration will be measured in whole blood and expressed in nmol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Whole-Blood Nicotinamide Adenine Dinucleotide (NAD+) Concentration
The concentration of oxidized nicotinamide adenine dinucleotide (NAD+) will be measured in whole blood and expressed in micromol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Relative Telomere Length in Peripheral Blood Cells
Relative telomere length in peripheral blood cells will be measured by quantitative real-time polymerase chain reaction (qPCR) and reported as a unitless value. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Peak Oxygen Uptake (Peak VO2)
Peak oxygen uptake will be measured during cardiopulmonary exercise testing and expressed in mL/min. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Oxygen Uptake at the Anaerobic Threshold (VO2-AT)
Oxygen uptake at the anaerobic threshold will be measured during cardiopulmonary exercise testing and expressed in mL/min. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Time frame: Baseline and Week 26
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Oct 2026, 16 months.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 16 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Mar 2027 → Oct 2026 and completion Mar 2027 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nicotinamide Mononucleotide